Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
May 30, 2023
In this webinar, Sebastien Clerc, PM in Cellenion, presents technologies Cellen ONE and Sphero ONE
Recent publication of in-vivo two-photon intravital imaging study targeting mouse kidney
May 22, 2023
In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal
formation and...
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
Cellenion’s solutions for isolation and sample preparation from Cells all the way to Spheroids
May 9, 2023
In this webinar, you will get an overview of Cellenion’s solutions for single cell and single 3D models applications:...
May 5, 2023
Decision to improve the output in a lab is always taken based on knowledge and workflow needs. But final decision to...
Real-Time and Quantitative Analysis of Macrophage Phagocytosis with RTCA eSight
May 4, 2023
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
A deep learning and Monte Carlo based framework for bioluminescence imaging center Maastro
Apr 20, 2023
"In this paper,we developed a framework using deep learning for bioluminescence-based targeting for GBM animal...
Striving for a cancer cure, one cell at a time
Mar 22, 2016
The mutations driving cancer create clonal populations that differ not just between cancer patients, but within individual tumors. These mutations contain small but significant populations which may survive treatment and metastasize. The only method to get a complete picture of tumor clonality is by sequencing single cells.
In this webinar, you will learn how you can make breakthrough discoveries in your research using single-cell DNA Sequencing. Dr. Ioannis Ragoussis of McGill University will share his research using single-cell whole exome sequencing to reveal the true heterogeneity and cell lineages present in triple negative breast cancer.
Brand profile
